Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
Barbara Błaszczyk1,2, Stanisław J Czuczwar3,4
1Department of Neurology, Neuropsychiatric Hospital, Kielce, Poland; 2Faculty of Health Sciences, High School of Economics and Law, Kielce, Poland; 3Department of Pathophysiology, Medical University, Lublin, Poland; 4Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland
Abstract: Epilepsy is a frequent, chronic disease demanding long-term medication with antiepileptic drugs (AEDs). When slow release formulations of AEDs are used the chance of compliance and control of seizures is increased. Lamotrigine (LTG) is a broad spectrum antiepileptic drug (AED), effective against both generalized and partial seizures. Its immediate-release formulation (LTG-IR) requires twice-daily dosing. In contrast, an extended-release formulation (LTG-XR) may be given once daily, providing a flatter dose-concentration curve with apparently lower maximum serum levels. Simplified dosing positively affects compliance and LTG-XR has a similar profile of efficacy and tolerability to LTG-IR. Rashes, including Stevens–Johnson syndrome, are the most serious adverse effect impacting 0.8% of pediatric patients. Thus, LTG-XR should be discontinued upon the appearance of rash.
Keywords: epilepsy, antiepileptic drugs, extended-release, lamotrigine, adverse reactions, tolerability, pharmacokinetics
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]